Diginex Expands Supply Chain Due Diligence Suite to Capitalize on Growing Regulatory Market
Summary
Diginex has expanded its supply chain due diligence product suite, integrating 'Risk-to-Remedy' and introducing new features to address accelerating regulatory pressure. This move positions the company to capitalize on the human rights and supply chain due diligence market, which is projected to grow from $3.8 billion in 2025 to $9.6 billion by 2034. The expansion leverages expertise from the prior acquisition of The Remedy Project. This product development occurs while the company is also managing the pending $1.5 billion all-stock acquisition of Resulticks, for which the long stop date was recently extended to June 12th.
At the time of this announcement, DGNX was trading at $1.09 on NASDAQ in the Technology sector, with a market capitalization of approximately $32M. The 52-week trading range was $0.89 to $318.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.